American Association for Cancer Research

CIMM at the Annual Meeting

The annual meeting is an extraordinary venue that fosters scientific discussions and helps build bridges across various disciplines. We encourage all meeting attendees to take advantage of the opportunities presented at the meeting to learn about the latest breakthroughs in cancer immunology, attend sessions outside your own areas of expertise and network with other scientists and clinicians interested in cancer immunology and immunotherapy.
  
The AACR Annual Meeting 2014 was held in San Diego, Calif., from April 5-9.

The Cancer Immunology Working Group (CIMM) hosted a variety of sessions and events at the annual meeting, including:


Cancer Immunology Working Group (CIMM) Town Meeting: Therapeutic Cancer Vaccines: Dinosaurs or Key Components?, co-sponsored by CIMM and Society for Immunotherapy of Cancer (SITC)
 

Tuesday, April 8, 2014
6:00 - 8:30 p.m.
Omni San Diego Hotel, Grand Ballroom ABC

Chairpersons:
Robert Vonderheide, M.D., DPhil., Abramson Family Research Cancer Institute of the University of Pennsylvania, Philadelphia, PA
Nina Bhardwaj, M.D., Ph.D., Icahn School of Medicine at Mt. Sinai Medical Center, New York, NY

This co-sponsored session offered an opportunity to hear from our colleagues in the AACR-Cancer Immunology (CIMM) Working Group and Society for Immunotherapy of Cancer (SITC) speak on "Therapeutic Cancer Vaccines: Dinosaurs or Key Components?" In addition to this exciting session, guests heard Dr. Glenn Dranoff, editor, speak about the one-year anniversary of the journal Cancer Immunology Research. Attendees also learned about other important CIMM initiatives, met members of the working group and steering committee, in addition to the opportunity to join the CIMM Working Group.

Speakers are:
Howard L. Kaufman, Rutgers Cancer Institute of New Jersey, New Brunswick, NJ
The role of oncolytic viruses in tumor immunotherapy

Francesco M. Marincola, Chief Research Officer, Sidra Medical and Research Center, Doha, Qatar
Basic concept for the understanding of cancer mediated immune rejection

Elizabeth M. Jaffee, Johns Hopkins University, Baltimore, MD
Vaccines: The ignitors of anti-tumor immunity


Joint Cancer Immunology (CIMM) / Tumor Microenvironment (TME) Working Groups
Evening Scientific Session: Collaboration of TME and Immune Responses in Irradiated Tumors

Monday, April 7, 2014
6:00-8:00 p.m.
San Diego Marriott Marquis and Marina, Marriott Hall, Salon 4

Tumor microenvironment and immunology are at an exciting crossroad. This jointly-sponsored session, "Collaboration of TME and Immune Responses in Irradiated Tumors," discussed tumor response to targeted radiotherapy mediated by the immune system. The chairpersons of the Cancer Immunology (CIMM) and Tumor Microenvironment (TME) Working Groups invited all working group members as well as all other interested annual meeting registrants to attend this evening scientific session to hear leaders from both fields present the most current information on this topic.

Chairpersons
Robert Vonderheide, M.D., DPhil., Abramson Family Research Cancer Institute of the University of Pennsylvania, Philadelphia, PA
Mary Helen Barcellos-Hoff, Ph.D., New York University School of Medicine, New York, NY

Speakers are:
Silvia Formenti, New York University, New York, NY
Radiation and Immunotherapy - the Role of the Tumor Microenvironment 

Charles G. Drake, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD
Effects of Radiation Therapy on Treg Infiltration of Tumors

Andy J. Minn, M.D., Ph.D., Abramson Family Research Cancer Institute of the University of Pennsylvania, Philadelphia, PA 
Insights into combining immune checkpoint blockade with radiation to treat metastatic melanoma


Other CIMM-Related Content (taking place at the San Diego Convention Center)

Award Lecture
Second Annual AACR-CRI Lloyd J. Old Award in Cancer Immunology
Wednesday, April 9, 2014, 10:00 a.m. - 11:00 a.m., Ballroom 20A-C 

Educational Sessions and Workshops

Beyond Ipilimumab and PD1/PD-L1 Pathway Blockade: Next Generation
Saturday, April 5, 2014, 8:00 a.m. - 10:00 a.m.; Room 33A-C

Tumor Immunology and Immunotherapy for Non-Immunologists
Saturday, April 5, 2014, 8:00 a.m. - 10:00 a.m., Ballroom 20D

Cancer Immunology for the Non-Immunologist - Tutorial
Saturday, April 5, 2014, 10:00 a.m. - 12:00 noon; Room 2

Novel Approaches to Re-Awakening the Immune System
Saturday, April 5, 2014, 10:15 a.m. - 12:15 p.m., Room 6CF

The Nature of Tumor Cell Death for the Control of Cancer: About Apoptosis, Necroptosis, Autophagy, Immunity and Metabolism
Saturday, April 5, 2014, 1:00 p.m. - 3:00 p.m., Room 7

Immune Modulation for the Treatment of Lung Cancer
Saturday, April 5, 2014, 1:00 p.m. - 3:00 p.m., Room 31A-C

Clinical Trial Designs Workshop: Design and Implementation of Innovative Clinical Trials: Part 4-Modality Combinations with Immune Checkpoint Blockade
Saturday, April 5, 2014, 3:15 p.m. - 5:15 p.m., Room 6B

Major Symposia

Association for Cancer Immunotherapy (CIMT)-AACR-CIMM Joint Session
Deciphering and Modulating T-cell specificity in clinically effective antitumor responses
Tuesday, April 8, 2014, 3:00 p.m. - 5:00 p.m., Room 25

Endogenous Immunity and Cancer
Monday, April 7, 2014, 10:30 a.m. - 12:30 p.m.; Room 6B

Immunoprevention in Cancer
Tuesday, April 8, 2014, 10:30 a.m. - 12:30 p.m.; Room 6B

Inflammation, Immunity and Cancer
Wednesday, April 9, 2014; 11:00 a.m. - 1:00 p.m.; Room 29A-D

Minisymposium

Immune-based Therapies: Responses, Biomarkers, and Mechanisms
Monday, April 7, 2014, 3:00 p.m. - 5:00 p.m.; Room 6CF

Meet-the-Expert

The Dominant Immune Suppressive Process in a Model of Pancreatic Ductal Adenocarcinoma: A Therapeutic Target
Sunday, April 6, 2014, 7:00 a.m. - 8:00 a.m., Room 28A-C

Recombinant Immunotoxins: From Conception to Clinical Reality in Mesothelioma and Leukemia
Monday, April 7, 2014, 7:00 a.m. - 8:00 a.m., Room 5

Chimeric Antigen Receptor Based Immunotherapy for Pediatric Cancer: Progress and Challenges
Wednesday, April 9, 2014, 7:00 a.m. - 8:00 a.m.

Plenary Sessions

Targeted Immunotherapy: Mobilizing the Immune System Against Cancer
Monday, April 7, 2014, 8:15 a.m. - 10:15 a.m.; Hall F-G

Novel Therapeutic Combinations in Cancer: Principles and Practice
Tuesday, April 8, 2014, 8:15 a.m. - 10:15 a.m., Hall F-G

Poster Sessions

Immune Mechanisms Invoked by Radiation, Chemotherapy, or Targeted Therapy
Sunday, April 6, 2014, 1:00 p.m. - 5:00 p.m.; Hall A-E, Poster Section 27

Therapeutic Antibodies
Sunday, April 6, 2014, 1:00 p.m. - 5:00 p.m.; Hall A-E, Poster Section 28

Inflammation and the Tumor Microenvironment
Monday, April 7, 2014, 8:00 a.m. - 12:00 noon; Hall A-E, Poster Section 28

Assessing Immune Responses to Interventional Therapies
Monday, April 7, 2014, 1:00 p.m. - 5:00 p.m.; Hall A-E, Poster Section 27

Immune Modulatory Agents and Interventions
Monday, April 7, 2014, 1:00 p.m. - 5:00 p.m.; Hall A-E, Poster Section 28

Antigen Presentation and Immune Regulation
Tuesday, April 8, 2014, 8:00 a.m. - 12:00 noon; Hall A-E, Poster Section 25

Immune Modulation in the Tumor Microenvironment
Tuesday, April 8, 2014, 8:00 a.m. - 12:00 noon; Hall A-E, Poster Section 26

Inflammation and Innate Immunity
Tuesday, April 8, 2014, 8:00 a.m. - 12:00 noon; Hall A-E, Poster Section 27

Adaptive Immunity and Immune Regulation
Tuesday, April 8, 2014, 1:00 p.m. - 5:00 p.m.; Hall A-E, Poster Section 9

Immune Checkpoint Inhibition
Wednesday, April 9, 2014, 8:00 a.m. - 12:00 noon; Hall A-E, Poster Section 10

Special Session

New SU2C Dream Teams: Patient Benefit Through Targeted Therapeutics and Immunotherapy
Monday, April 7, 2014, 3:15 p.m. - 5:15 p.m.; Room 6B